Subgroup analysis
ADVERSE EVENTS
The IP/IC plus camrelizumab showed better PFS than EP/EC plus PD-L1 inhibitor among all subgroups, but the difference was not statistically significant (Kaplan-Meier curves of progression-free survival by immune-related adverse events (irAEs) in the irAE-evaluable population.